12/31
12:00 pm
vinc
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - VINC, VCSA, MRNS, MHLD
Low
Report
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - VINC, VCSA, MRNS, MHLD
12/30
10:17 am
vinc
VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders
High
Report
VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders
12/30
09:30 am
vinc
Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Medium
Report
Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
12/27
04:05 pm
vinc
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
High
Report
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
12/4
06:53 am
vinc
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 [Yahoo! Finance]
Medium
Report
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 [Yahoo! Finance]
12/4
06:45 am
vinc
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
High
Report
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
11/12
09:00 am
vinc
Vincerx Pharma Reports Third Quarter 2024 Financial Results
Medium
Report
Vincerx Pharma Reports Third Quarter 2024 Financial Results
10/8
11:48 am
vinc
Vincerx Pharma, Inc. (NASDAQ: VINC) had its price target lowered by analysts at Leerink Partners from $4.00 to $2.00. They now have an "outperform" rating on the stock.
High
Report
Vincerx Pharma, Inc. (NASDAQ: VINC) had its price target lowered by analysts at Leerink Partners from $4.00 to $2.00. They now have an "outperform" rating on the stock.
10/7
04:05 pm
vinc
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
High
Report
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates